KU Leuven, Leuven, Belgium.
Calcif Tissue Int. 2020 Jan;106(1):76-87. doi: 10.1007/s00223-019-00591-4. Epub 2019 Jul 26.
Patients with respiratory diseases such as cystic fibrosis, chronic obstructive pulmonary disease, or asthma often experience an acute worsening of respiratory symptoms, termed exacerbations. Although the course of exacerbations is disease specific, they are mostly triggered by a respiratory infection. Exacerbations often require hospitalization and are an important cause of mortality. Treatments of exacerbations aim to minimize the negative impact and to prevent subsequent events. Despite many existing therapy options, many patients do not benefit from therapy and suffer from recurrent events. Vitamin D deficiency is a worldwide problem and is extremely prevalent in these patients. Vitamin D, known for its calcemic effects, also has immunomodulatory and anti-infectious actions and can therefore be a possible agent to treat or prevent exacerbations. This review will focus on vitamin D as a potential candidate to treat or prevent exacerbations in CF, COPD, and asthma.
患有囊性纤维化、慢性阻塞性肺疾病或哮喘等呼吸系统疾病的患者经常会出现呼吸症状的急性恶化，这种情况被称为加重。尽管加重的过程因疾病而异，但它们大多是由呼吸道感染引发的。加重通常需要住院治疗，是导致死亡的一个重要原因。加重的治疗旨在将负面影响降到最低，并预防后续事件的发生。尽管有许多现有的治疗选择，但许多患者并没有从治疗中受益，而是反复发作。维生素 D 缺乏是一个全球性问题，在这些患者中极为普遍。维生素 D 以其钙调节作用而闻名，它还具有免疫调节和抗感染作用，因此可以成为治疗或预防加重的潜在药物。这篇综述将重点讨论维生素 D 作为治疗 CF、COPD 和哮喘加重的潜在候选药物。
